DAREON-NEC-1: what clinicians are saying
obrixtamig in first-line DLL3-positive advanced extrapulmonary neuroendocrine carcinomas · NCT07544654 ↗ · Phase 3 · Boehringer Ingelheim
A physician described in the sources as presenting DAREON-NEC-1 sees chemotherapy resistance as a reason to investigate obrixtamig, while cautioning that patients may gain no benefit. Their participation advice weighs CRS observation and travel demands against uncertain personal benefit, with timely DLL3 assessment shaping access. Separately, a speaker whose clinical role is unstated questions how treatment duration would affect interpretation of a future survival advantage. This trial’s outcomes are not reported in the sources reviewed for this edition.
Created with AI · how we check it
- edition 1
- commentary checked Nov 15, 2026
- 58 verified statements
This edition $750, with MCP access for your AI agent. Get this report
9 findings, and what sits behind each
01. One clinician hopes for longer control, survival and preserved quality of life while warning benefit remains uncertain
1 of the report's 3 cited clinicians · 8 statements from 1 speaker in 2 sources, all podcasts or videos · 6 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Overall survival (OS), Secondary endpoints, Population and setting, Safety and tolerability.
02. One X account questions what a survival win would mean when treatment durations differ
1 of the report's 3 cited clinicians · 7 statements from 1 speaker in 2 sources, 1 of them a podcast or video · 5 passages
Limitations recorded: 2.
Draws on: The comparison, Design and conduct, Primary endpoint: Overall survival (OS), Population and setting.
03. One clinician warns that initial regimen choices and DLL3 testing can determine trial access
1 of the report's 3 cited clinicians · 9 statements from 1 speaker in 1 source, a podcast or video · 4 passages
Limitations recorded: 2.
Draws on: Population and setting, Design and conduct.
04. One clinician says CRS appears mostly manageable but stresses intensive early monitoring
1 of the report's 3 cited clinicians · 9 statements from 1 speaker in 1 source, a podcast or video · 4 passages
Limitations recorded: 2.
Draws on: Safety and tolerability, Secondary endpoints, Design and conduct, Primary endpoint: Overall survival (OS).
05. One clinician acknowledges local chemotherapy as a real counterweight to trial enrollment
1 of the report's 3 cited clinicians · 13 statements from 1 speaker in 2 sources, all podcasts or videos · 5 passages
Limitations recorded: 3.
Draws on: Primary endpoint: Overall survival (OS), Safety and tolerability, Design and conduct, Secondary endpoints, The comparison.
06. One X account anticipates DLL3 workflow and specialist-readiness barriers to adoption
No named clinician · accounts and unnamed speakers · 2 statements in 1 source · 1 passage
Limitations recorded: 2.
Draws on: Safety and tolerability.
07. One X account hopes lung-cancer maintenance results can be replicated in epNEC
2 of the report's 3 cited clinicians · 2 statements from 2 speakers in 1 source · 3 passages
Limitations recorded: 2.
08. One X account reads indication selection as competitive positioning and predicts class-wide stakes
No named clinician · accounts and unnamed speakers · 2 statements in 1 source · 1 passage
Limitations recorded: 2.
Beyond the trial population
09. One account discusses phase Ib DAREON-7 responses and DLL3-high PFS pending randomized survival evidence; another relays a question about increased CRS with high DLL3
1 of the report's 3 cited clinicians · 4 statements from 2 speakers in 2 sources · 2 passages
Limitations recorded: 3.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 9
1 of the report's 3 cited clinicians
One clinician hopes for longer control, survival and preserved quality of life while warning benefit remains uncertain
8 statements from 1 speaker in 2 sources, all podcasts or videos
- 8
- statements
- 6
- passages
- 2
- sources
- 1
- speaker
What the statements areViews 3Questions and uncertainty 2Clinical experience 1Comparisons 0Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 9Giving context 1Recorded with the findingLimitations: 3
2 podcasts and video
Draws on: Primary endpoint: Overall survival (OS), Secondary endpoints, Population and setting, Safety and tolerability.
- Beyond the trial population
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
1 of the 9 findings and 4 of the 58 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.
Abbreviations (7)
CRS, cytokine release syndrome; HCP, healthcare professional; ICANS, immune effector cell-associated neurotoxicity syndrome; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; PFS, progression-free survival.
The full DAREON-NEC-1 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians need DAREON-NEC-1 to show about duration of cancer control, survival, quality of life, CRS and ICANS when adding obrixtamig to first-line chemotherapy for DLL3-positive advanced extrapulmonary neuroendocrine carcinoma?
From finding F1 (8 statements from 1 speaker in 2 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 10commentary sources screened
- 6sources cited by verified statements
- 5named in screened sources
- 4speakers cited in the report
- 4cited speakers with a verified identity
3 cited clinicians, speakers with a confirmed clinical role, of them 3 physicians. By role and specialty:
- 1 physician, specialty not confirmed
- 1 physician, Hematology and oncology
- 1 physician, Medical oncology
Also in the sources: 1 organizational or shared account, not counted as people.
- 58verified statements, each linked to its source
- 41of them from speakers with a confirmed clinical role
- 9findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 9 | Titles free |
| Detailed analysis | 11 sections | Paid |
| Verified statements with short source quotes and links | 58 | Paid |
| Who said each statement: the cited speakers | 4 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 3 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
13 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Overall survival (OS) | 5 | 3 |
| Secondary endpoints | 4 | 1 |
| Population and setting | 8 | 3 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 8 | 3 |
| Safety and tolerability | 8 | 2 |
| Design and conduct | 11 | 2 |
| DLL3 assessment, treatment rationale and adoption infrastructure | 9 | 3 |
| Eligibility and initial regimen choices | 7 | 1 |
| Participation trade-offs, equitable access and patient support | 16 | 2 |
| Time-specific recruitment and site access | 4 | 3 |
| Earlier DAREON-7 activity and unresolved DLL3 subgroup questions | 4 | 2 |
| Maintenance hopes informed by small-cell lung cancer | 2 | 1 |
| Commercial positioning and conditional class-wide interpretations | 2 | 1 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
58 verified statements from 6 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 44 statements · 76% | ||||
| YouTube | 44 | 2 | 2 | |
| Posts · 14 statements · 24% | ||||
| X threads | 14 | 4 | 8 | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 5 / quarter
- Screened window
- Jun 4, 2026 → Nov 10, 2026
- Cited window
- Jun 4, 2026 → Nov 10, 2026
- Retrieved
- Nov 15, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase III, Multi-center, Open-label, Randomised, Controlled Trial of Intravenous Obrixtamig in Combination With Carboplatin and Etoposide vs. Carboplatin and Etoposide as First-line Therapy in DLL3-positive Patients With Unresectable Locally Advanced or Metastatic Extrapulmonary Neuroendocrine Carcinomas
- Registry
- NCT07544654
- Study IDs
- 1438-0011 · 2025-523869-22-00 (CTIS) · U1111-1328-6623 (WHO International Clinical Trials Registry Platform (ICTRP))
- Sponsor
- Boehringer Ingelheim
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Recruiting
- Enrollment
- 390 estimated
- Registered
- 2026-04-22
- Start
- 2026-07-10 actual
- Primary completion
- 2029-12-13 estimated
- Primary endpoint
- Overall survival (OS)
- Interventions
- 4 registered
More on: Neuroendocrine carcinoma
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Not yet captured in this edition: a view on the promise of upfront obrixtamig plus chemotherapy evidence.
- 1 more clinician view in the sources used in this report is not yet captured as evidence in this edition.
- Discussion that does not name the trial may be missing from this edition.
- 4 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 40 sources about other trials or topics are not included.
Show all 14 known gaps +Fewer −
- The sources reviewed for this edition are not a representative sample of HCP opinion, and the number of sources does not establish the number of independent clinical perspectives.
- Most detailed eligibility, safety and participation guidance comes from a speaker, whom the source describes as presenting DAREON-NEC-1. Another speaker describes presenting the phase Ib DAREON-7 data underlying their favorable interpretation. These views should not be treated as independent external appraisals of those respective studies.
- The relevant NCF conference passages do not establish the speaker's identity. They cannot safely be assigned to the person named in the video's title or description.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- No DAREON-NEC-1 efficacy or safety readout appears in the material reviewed. DAREON-7 activity reports and extensive-stage small-cell lung cancer maintenance findings must not be substituted for its outcomes.
- No protocol was listed in the registry information reviewed, no publication for the exact trial was identified, and no exact obrixtamig label was identified. Detailed protocol or current regulatory conclusions cannot be drawn from the commentary.
- Discussion that never names the trial or recognizable aliases may be absent. Missing commentary cannot establish that clinicians have no view on an issue.
- Recruitment and monitoring comparisons are time-specific source statements. They do not establish current site availability, eventual labeling or present-day comparative requirements.
- Post and video publication dates do not establish presentation dates or changes of opinion.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 1 fix (names, counts, tags, text)
None of these changed a statement, finding or source.
- Nov 15, 2026 UTCCorrected to match the delivered report: 58 verified statements (was 54); 41 statements from speakers with a confirmed clinical role (was 38); 9 findings (was 8); finding titles; per-finding counts; publication caveats beside findings; trial aspects; section headings; source breakdowns; the indications and therapeutic areas the report is listed under; the limitations; source quotations and links in the paid report. Finding titles on this page say what speakers discuss, with no word judging benefit or harm; the report keeps its own titles.
Last checked for new commentary Nov 15, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. DAREON-NEC-1 (NCT07544654): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 15, 2026. https://www.erudio.com/reports/dareon-nec-1-nct07544654
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "DAREON-NEC-1" (NCT07544654), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "dareon-nec-1-nct07544654". If you cannot make requests, read https://www.erudio.com/reports/dareon-nec-1-nct07544654.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT07544654", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a wallet with a payment client for HTTP 402 (MPP with USDC on Tempo, or x402 with USDC on Base) and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT07544654 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/dareon-nec-1-nct07544654.json
curl https://www.erudio.com/reports/dareon-nec-1-nct07544654.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "dareon-nec-1-nct07544654" })release a361d727cdfef8c0a6badcf0b68982e8560b4fec2af0010248b32de95b6372ad
Questions
How much does the DAREON-NEC-1 report cost?
One edition costs $750 (Focused · 58 verified statements · 41 from 3 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the DAREON-NEC-1 report cover?
58 statements from 6 sources (2 videos, 4 posts), 41 of them from 3 confirmed clinicians, each linked to its source. Commentary checked Nov 15, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the DAREON-NEC-1 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "dareon-nec-1-nct07544654" }) previews it and create_order({ "report": "dareon-nec-1-nct07544654", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the DAREON-NEC-1 report?
Edition 1 (version 1.0.0), accepted Nov 15, 2026 UTC; last checked for new commentary Nov 15, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.